ATOS
Atossa Genetics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$44.35M
P/E Ratio
—
EPS
$-4.04
Beta
1.34
52W High
$19.35
52W Low
$3.76
50-Day MA
$5.39
200-Day MA
$10.51
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
7.04
PEG Ratio
0.00
About Atossa Genetics Inc
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs in the areas of oncology and infectious diseases. The company is headquartered in Seattle, Washington.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-37.13M |
| Operating Margin | 0.00% |
| Return on Equity | -62.70% |
| Return on Assets | -37.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.57 |
| Price-to-Book | 1.17 |
| Price-to-Sales (TTM) | 1872.06 |
| EV/Revenue | 3287.25 |
| EV/EBITDA | 2.00 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $8.61M |
| Float | $8.61M |
| % Insiders | 0.83% |
| % Institutions | 21.44% |
Analyst Ratings
Consensus ($43.75 target)
1
Strong Buy3
BuyData last updated: 4/7/2026